Nicolas Fabresse

Dr. Nicolas Fabresse

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2018 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
ILIslam Amine LARABI
Islam Amine LARABI
MMMarie Martin
Marie Martin
IEIsabelle Etting
Isabelle Etting
PPPauline Penot
Pauline Penot
NFNicolas Fabresse
Nicolas Fabresse
JAJean Claude Alvarez
Jean Claude Alvarez

5 November 2018 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
NFNicolas Fabresse
Nicolas Fabresse
ILIslam Amine LARABI
Islam Amine LARABI
TSTim Stratton
Tim Stratton
RMRobert Mistrik
Robert Mistrik
GPGregory Pfau
Gregory Pfau
JAJean Claude Alvarez
Jean Claude Alvarez

28 December 2018 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
NFNicolas Fabresse
Nicolas Fabresse
HAHassan Aouad
Hassan Aouad
AKAdeline Knapp
Adeline Knapp
CMCharlotte Mayer
Charlotte Mayer
IEIsabelle Etting
Isabelle Etting
JAJean Claude Alvarez
Jean Claude Alvarez

1 August 2021 in Forensic Science International
Verified
Journal Article
Closed access
HMHilel Mehamha
Hilel Mehamha
NDNatalia Doudka
Natalia Doudka
PMPhilippe Minodier
Philippe Minodier
NNNadège Néant
Nadège Néant
BLBruno Lacarelle
Bruno Lacarelle
NFNicolas Fabresse
Nicolas Fabresse

26 January 2022 in Toxics
Verified
Journal Article
Open access
PDF file
AHAtakan Hernandez
Atakan Hernandez
VLValerie Lacroze
Valerie Lacroze
NDNatalia Doudka
Natalia Doudka
JBJenny Becam
Jenny Becam
CPCarole Pourriere-Fabiani
Carole Pourriere-Fabiani
NFNicolas Fabresse
Nicolas Fabresse
The aim of this study was to develop and to validate a toxicological untargeted screening relying on LC-HRMS in meconium including the detection of the four main classes of drugs of abuse (DoA; amphetamines, cannabinoids, opioids and cocaine). The method was then applied to 29 real samples. Analyses were performed with a liquid chromatography system coupled to a benchtop Orbitrap operating in a data-dependent analysis. The sample amount was 300 mg of meconium extracted twice by solid phase extraction following two distinct procedures. Raw data were processed using the Compound Discoverer 3.2 software (Thermo). The method was evaluated and validated on 15 compounds (6-MAM, morphine, buprenorphine, norbuprenorphine, methadone, EDDP, amphetamine, MDA, MDMA, methamphetamine, cocaine, benzoylecgonine, THC, 11-OH-THC, THC-COOH). Limits of detection were between 0.5 and 5 pg/mg and limits of identification between 5 and 50 pg/mg. Mean matrix effect was between −79 and −19% (n = 6) and mean overall recovery between 18 and 73% (n = 6) at 100 pg/mg. The application allows the detection of 88 substances, including 47 pharmaceuticals and 15 pharmaceutical metabolites, cocaine and its metabolites, THC and its metabolites, and natural (morphine, codeine) and synthetic (methadone, buprenorphine, tramadol, norfentanyl) opioids. This method is now used routinely for toxicological screening in high-risk pregnancies

1 January 2022 in Toxicologie Analytique et Clinique
Verified
Journal Article
Closed access
EZEliès Zarrouk
Eliès Zarrouk
MLMarie Lenski
Marie Lenski
CBClément Bruno
Clément Bruno
VTValérie Thibert
Valérie Thibert
PCPaul Contreras
Paul Contreras
NFNicolas Fabresse
Nicolas Fabresse